Eunkyung Song1, Huanyu Wang, Adriana E Kajon, Doug Salamon, Siwen Dong, Octavio Ramilo, Amy Leber, Preeti Jaggi. 1. From the *Division of Pediatric Infectious Diseases and †Department of Pathology and Laboratory Medicine, Nationwide Children's Hospital, Columbus, Ohio; ‡Infectious Disease Program, Lovelace Respiratory Research Institute, Albuquerque, New Mexico; and §The Ohio State University, Columbus, Ohio.
Abstract
BACKGROUND: Human adenovirus (HAdV), especially species C (HAdV-C), can be detected incidentally by polymerase chain reaction in nasopharyngeal (NP) samples, making it difficult to interpret clinical significance of a positive result. We classified patients into groups based on HAdV culture positivity from respiratory specimens and the presence of an identified co-pathogen. We hypothesized that HAdV-C would be over-represented and viral burden would be lower in patients most likely to have incidental detection (ie, with a negative viral culture and documented co-pathogen). METHODS: Immunocompetent children with HAdV + nasopharyngeal specimens were classified into 4 groups: group I (HAdV culture (+) and no co-infection), group II (culture (+) and co-infection), group III (culture (-) and no co-infection) and group IV (culture (-) and co-infection). Viral burden (cycle threshold) and species were compared among groups. RESULTS: Of 483 nasopharyngeal specimens, HAdV was isolated in culture in 252 (52%); co-infection was found in 265 (55%) patients. Group I (most consistent with acute disease) had significantly lower cycle thresholds (median 23.9; interquarile range 22.2-28.1) compared with group IV (most consistent with incidental detection; median 37.3; interquarile range 35.3-38.9; P < 0.0001). HAdV-C accounted for 41% samples of group I and 83% of group IV (P < 0.0001). We identified a subset of 22 patients with bacterial or fungal co-pathogens, 18 of whom had no growth on viral culture (group IV) with a median cycle threshold of 37.4 (interquarile range 33.9-39.2). CONCLUSIONS: Species identification and viral burden may assist in interpretation of a positive HAdV result. Low viral burden with HAdV-C may be consistent with incidental detection.
BACKGROUND:Human adenovirus (HAdV), especially species C (HAdV-C), can be detected incidentally by polymerase chain reaction in nasopharyngeal (NP) samples, making it difficult to interpret clinical significance of a positive result. We classified patients into groups based on HAdV culture positivity from respiratory specimens and the presence of an identified co-pathogen. We hypothesized that HAdV-C would be over-represented and viral burden would be lower in patients most likely to have incidental detection (ie, with a negative viral culture and documented co-pathogen). METHODS: Immunocompetent children with HAdV + nasopharyngeal specimens were classified into 4 groups: group I (HAdV culture (+) and no co-infection), group II (culture (+) and co-infection), group III (culture (-) and no co-infection) and group IV (culture (-) and co-infection). Viral burden (cycle threshold) and species were compared among groups. RESULTS: Of 483 nasopharyngeal specimens, HAdV was isolated in culture in 252 (52%); co-infection was found in 265 (55%) patients. Group I (most consistent with acute disease) had significantly lower cycle thresholds (median 23.9; interquarile range 22.2-28.1) compared with group IV (most consistent with incidental detection; median 37.3; interquarile range 35.3-38.9; P < 0.0001). HAdV-C accounted for 41% samples of group I and 83% of group IV (P < 0.0001). We identified a subset of 22 patients with bacterial or fungal co-pathogens, 18 of whom had no growth on viral culture (group IV) with a median cycle threshold of 37.4 (interquarile range 33.9-39.2). CONCLUSIONS: Species identification and viral burden may assist in interpretation of a positive HAdV result. Low viral burden with HAdV-C may be consistent with incidental detection.
Authors: Mark A Poritz; Anne J Blaschke; Carrie L Byington; Lindsay Meyers; Kody Nilsson; David E Jones; Stephanie A Thatcher; Thomas Robbins; Beth Lingenfelter; Elizabeth Amiott; Amy Herbener; Judy Daly; Steven F Dobrowolski; David H-F Teng; Kirk M Ririe Journal: PLoS One Date: 2011-10-19 Impact factor: 3.240
Authors: Varvara Probst; Emily K Datyner; Zaid Haddadin; Danielle A Rankin; Lubna Hamdan; Herdi K Rahman; Andrew Spieker; Laura S Stewart; Claudia Guevara; Erin Yepsen; Jonathan E Schmitz; Natasha B Halasa Journal: J Clin Virol Date: 2020-12-11 Impact factor: 3.168
Authors: Amy L Leber; Jan Gorm Lisby; Glen Hansen; Ryan F Relich; Uffe Vest Schneider; Paul Granato; Stephen Young; Josep Pareja; Irene Hannet Journal: J Clin Microbiol Date: 2020-04-23 Impact factor: 5.948
Authors: Carmen L Charlton; Esther Babady; Christine C Ginocchio; Todd F Hatchette; Robert C Jerris; Yan Li; Mike Loeffelholz; Yvette S McCarter; Melissa B Miller; Susan Novak-Weekley; Audrey N Schuetz; Yi-Wei Tang; Ray Widen; Steven J Drews Journal: Clin Microbiol Rev Date: 2018-12-12 Impact factor: 26.132
Authors: Xinwei Wu; Xiaoyan Lu; Eileen Schneider; Jamal A Ahmed; M Kariuki Njenga; Robert F Breiman; Rachel B Eidex; Dean D Erdman Journal: J Med Virol Date: 2018-11-08 Impact factor: 2.327